Introduction
Temozolomide (TZM) is a triazene compound which has shown activity in patients with metastatic melanoma and high-grade astrocytomas. 1, 2 In addition, a possible clinical use of TZM for the treatment of leukemias, could be inferred from the results of a pilot clinical study, performed with the methylating triazene dacarbazine. 3 This study pointed out that dacarbazine could have a therapeutic potential for acute nonlymphoid leukemias relapsed or refractory to standard chemotherapy. Actually, metabolism of dacarbazine generates a methylating species which is the same product derived from the spontaneous hydrolysis of TZM and which accounts for the biological activity of both drugs. 4 Differently from dacarbazine, TZM has limited bone marrow toxicity and penetrates across the blood-brain barrier.
The antitumor activity of TZM has been attributed to the methylation of DNA at different base positions. At least 70% of the DNA adducts are located at N 7 -guanine, whereas 9% and 5% adducts occur at N 3 -adenine and O 6 -guanine, respectively. 4 Methyl adducts at O 6 -guanine are rapidly removed from DNA by the O 6 -alkylguanine DNA alkyltransferase (OGAT). 5 If not repaired prior to DNA replication, O 6 -methylguanine pairs inappropriately either with thymine or with cytosine, and triggers the intervention of the mismatch repair system (MRS). 6 Futile attempts of the MRS to find a complementary base for O 6 -methylguanine result in generation of DNA strand breaks, which can trigger apoptosis. 7 Thus, tumor cell susceptibility to the cytotoxic effects of O 6 -methylguanine requires a functional MRS. 8 Cells endowed with high levels of OGAT activity and with a normal MRS, can still be sensitized to methylating agents by O 6 -benzylguanine, a potent OGAT inhibitor. 9 In contrast, OGAT-proficient cells with a deficiency in the MRS function, are tolerant to the methylation damage, even after depletion of OGAT activity. 10, 11 The N 3 -methyladenine and N 7 -methylguanine adducts are repaired by the base excision repair system (BER). Although, N 3 -methyladenine is generally repaired from DNA more rapidly than O 6 -methylguanine, 12 there is strong evidence that the presence of N 3 -methyladenine DNA adduct is cytotoxic. 13 In contrast, N 7 -methylguanine appears to have little or no lethal effect. 12 The DNA repair process by BER proceeds through a sequence of reactions requiring the intervention of several enzymes. The first step consists in the removal of the damaged base by DNA glycosylases. In particular, the mammalian 3-methylpurine-DNA glycosylase (MPG) hydrolizes the N-glycosidic bond of N 3 -methyladenine and displays a broad substrate range, including N 7 -methylguanine. 14 The removal of the base is followed by the strand cleavage induced by an apurinic/apyrimidinic endonuclease. Subsequently, the single nucleotide gap filling requires the co-ordinate intervention of DNA polymerase ␤, X-ray repair cross-complementing 1 (XRCC1), ligase 1 and 3, which all act in complexes. 15 The strand breaks, generated by the enzymatic excision, recruit the poly(ADP-ribose) polymerase (PADPRP) which, following DNA binding, synthesizes and catalyzes the transfer of poly (ADP-ribose) to itself and to a number of nuclear proteins. 16 Thus, it has been suggested that PADPRP might act as nicksensor and play a role in the targeting of BER components to the damaged DNA site. 15, 17 Actually, PADPRP associates with XRCC1, a partner of enzymatic components of BER. In particular, XRRC1 associates with DNA polymerase ␤ and ligase 3 and it is suggested to act as a scaffold protein during the repair of DNA damage by BER. 18 We have previously demonstrated that leukemic blasts with low levels of OGAT are susceptible to the cytotoxic effects of TZM 19 and that apoptosis is involved in the mechanism of leukemic cell death. 10 Recently, we have shown that PADPRP inhibitors potentiate apoptosis by TZM either in OGAT-proficient or OGAT-deficient human leukemic cell lines. 20 In addition, it has been reported that PADPRP inhibitors might be of potential value to reduce resistance of MRS-deficient leukemic cells to TZM. 11, 21 The aim of the present study was to investigate the kinetics of apoptosis induction observed after exposure of MRSdeficient Jurkat leukemic cells 22 to TZM associated with PADPRP inhibitors. Moreover, we have also explored whether the combined treatment might be accompanied by modulation of the expression of PADPRP or of other molecules involved in BER (ie MPG and XRCC1). The results showed that the cytotoxic and apoptotic effects of TZM associated with PADPRP inhibitors were evident as early as 24 h after drug exposure of Jurkat cells, thus indicating that completion of cell division was not required for the emergence of cytotoxicity induced by the drug combination. Moreover, increase of PADPRP or MPG transcripts was observed after Jurkat cell treatment either with TZM alone or associated with PADPRP inhibitors, whereas XRCC1 transcript was positively modulated only in the case of the drug combination. These data suggest that the PADPRP and MPG are involved in the processing of methyl adducts generated by TZM and that persistence of strand breaks selectively triggers resynthesis of XRCC1.
Materials and methods

Cell culture
Jurkat cells were cultured in RPMI-1640 (Gibco, Paisley, UK) supplemented with 10% heat inactivated (56°C, 30 min) fetal calf serum (Gibco), 2 mM L-glutamine, and antibiotics (Flow Laboratories, McLean, VA, USA), at 37°C in a 5% CO 2 humidified atmosphere.
Drugs
TZM was kindly provided by Schering-Plough Research Institute (Kenilworth, NJ, USA). The PADPRP inhibitor 3-aminobenzamide (ABZ) was purchased from Sigma (St Louis, MO, USA), whereas the more specific PADPRP inhibitor 8-hydroxy-2-methylquinazolin-4[3H]-one (NU1025) 23 was a kind gift of Roger J Griffin (Department of Chemistry, University of Newcastle upon Tyne, Newcastle upon Tyne, UK). TZM stock solutions were prepared by dissolving the drug in DMSO; ABZ and NU1025 were dissolved in RPMI-1640.
Drug treatment and cell growth evaluation
Cells were cultured in flasks (Falcon, Becton Dickinson Labware, Oxnard, CA, USA) at the concentration of 3 × 10 5 cells/ml. TZM was added to the culture medium at final concentrations ranging between 125 and 500 M. Inhibition of PADPRP was obtained by treating the cells with 4 mM ABZ or 10 M NU1025, concentrations which have been described to inhibit PADPRP activity. 24 Cells were then incubated at 37°C for 3 days and cell growth was evaluated in terms of count of viable cells, every 24 h. Cells were manually counted in quadruplicate, using a hemocytometer and cell viability was determined by trypan blue exclusion test. Cell line chemosensitivity to TZM combined with PADPRP inhibitors was evaluated in terms of IC 50 , ie the concentration of the drug, expressed in M, capable of inhibiting cell growth by 50%. The IC 50 s values were calculated on the regression line in which the number of viable cells was plotted vs the logarithm of the drug concentration.
Pulsed field gel electrophoresis (PFGE)
PFGE of high molecular weight DNA fragments and preparation of plugs were performed according to Walker et al. 25 Briefly, cells (2 × 10 6 ) were harvested from culture, washed twice with ice-cold PBS, resuspended in 1.0 ml of a buffer containing 0.15 M NaCl, 2 mM KH 2 PO 4 /KOH (pH 6.4), 1 mM EGTA and 5 mM MgCl 2 , centrifuged at 170 g for 2 min and washed again twice with 100 l of the same buffer. Cells were resuspended in 50 l of this buffer and mixed with an equal volume of molten 1.5% low melting point agarose and 0.4 mg/ml of proteinase K. The agarose blocks were placed in 1 ml of 10 mM NaCl, 10 mM Tris-HCl, pH 9.5, 25 mM EDTA, 1% N-lauroylsarcosine supplemented with 0.1 mg/ml of proteinase K and incubated at 37°C for 3 h. Plugs were then rinsed in three changes of 10 mM Tris-HCl, pH 8.0, 1 mM EDTA at 4°C for 10 min each. Electrophoresis was carried out using a switch back power supply (Hoefer Scientific, San Francisco, CA, USA). The gels (1.5% agarose) were run at 200 V at 4°C in 45 mM Tris/borate and 1 mM EDTA, pH 8.3, containing ethidium bromide (0.5 g/ml), with the ramping rate changing from T1 = 0.5 s and T2 = 10 s for 16 h, with a forward to backward ratio of 3. DNA was visualized under UV light and photographed using a Polaroid camera set-up.
Western blotting
Cell pellets were resuspended in hypotonic buffer (10 mM Tris-HCl, 1 mM EDTA, pH 7.4 and freshly added 1 mM phenylmethyl-sulfonyl-fluoride) and centrifuged at 10 000 g. An aliquot of the supernatants was saved for protein concentration determination, and the rest immediately boiled in SDS sample buffer (50 mM Tris-HCl pH 6.8, 100 mM dithiothreitol, 2% SDS, 0.1% bromophenol blue, 10% glycerol). One hundred micrograms of proteins per sample were electrophoresed on 10% SDS-polyacrylamide gels. Afterwards, proteins were transferred on Hybond-C membrane (Amersham, Buckinghamshire, UK). Filters were blocked with 3% non-fat dry milk in TBST (20 mM Tris-HCl pH 8.0, 0.9% NaCl, 0.03% Tween 20) and then incubated with anti-PADPRP monoclonal antibody C-2-10 (Clontech, Palo Alto, CA, USA). Complexes were visualized using an alkaline phosphatase-coupled anti-mouse IgG antibody and the Protoblot colour development system (Promega Biotech, Madison, WI, USA).
Assessment of apoptosis by flow cytometry analysis
Cells from cultures were washed with PBS and fixed in 70% ethanol at −20°C for 18 h. The centrifuged pellets were resuspended in 1 ml of hypotonic solution containing propidium iodide (PI) (50 g/ml), 0.1% sodium citrate, 0.1% Triton-X, and RNase (10 g/ml). Cells were incubated in the dark, at 37°C for 15 min. Data collection was gated utilizing forward light scatter and side light scatter to exclude cell debris and cell aggregates. The PI fluorescence was measured on a linear scale using a FACSscan flow cytometer (Becton Dickinson, San Jose CA, USA). Apoptotic cells are represented by a broad hypodiploid peak, which is easily discriminable from the narrow peak of cells with diploid DNA content in the red fluor-escence channel. All data were recorded and analyzed using Lysis II software (Becton Dickinson).
Confocal laser scanning microscopy
Morphological analysis of the apoptotic modifications was carried out in cells fixed with 2% paraformaldehyde in PBS for 15 min at room temperature and applied to poly-L-lysinecoated cover slips. After staining of the nuclei with 2 g/ml PI and 0.1 mg/ml RNase for 5 min at room temperature, coverslips were mounted on glass microscope slides, in the presence of glycerol/PBS at the ratio 4:1. Slides were observed on a LEICA TCS 4D confocal laser scanning microscope, supplemented with an argon/kripton laser and equipped with 40 × 1.0-0.5 and 100 × 1.3-0.6 oil immersion lenses (Leitz, Wetzlar, Germany). The excitation and the emission wavelenghts employed were 488 nm and 590 nm, respectively. The acquisitions were recorded, employing the pseudocolour representation.
Northern blot analysis
Total cellular RNA was extracted using the TriPure isolation reagent (Boehringer Mannheim, Milan, Italy). RNAs (15 g) were fractionated by electrophoresis on a formaldehydecontaining 1.2% agarose gel. The integrity of RNA was confirmed by RNA visualization, adding ethidium bromide to the RNA gel loading buffer. RNA was transferred to nylon membrane (Gene Screen Plus; New England Nuclear, Boston, MA, USA) and hybridized at 68°C for 1 h with a 32 P-labeled probe, using the QuickHyb hybridization solution (Stratagene, Cambridge, UK). Washing of the blots was performed twice in 2 × SSC (1 × SSC = 0.1 sodium chloride, 0.015 M sodium citrate) and 0.1% SDS at room temperature for 15 min and once in 0.1 × SSC and 0.1% SDS at 60°C for 30 min, according to the manufacturer's instructions. The blotted membrane was exposed to X-ray film (Kodak, Rochester, NY, USA) at −80°C.
The DNA probes used for the detection of PADPRP and XRCC1 transcripts were obtained by polymerase chain reaction (PCR) of genomic DNA (1 g) derived from normal peripheral blood lymphocytes. The primer pairs used were 5Ј-TCGCCCATGTTTGATGGAAA-3Ј and 5Ј-CTGTCACTC-CTCCAGCTTC-3Ј, which correspond to nucleotide positions 11-30 and 176-158, respectively, of the human PADPRP DNA sequence (accession number M29545) and allow amplification of a 167 bp fragment, corresponding to exon 2. The primer pairs used for XRCC1 were: 5Ј-TGCCAG-CTCCAACTCGTACCCCA-3Ј and 5Ј-ATGAGGTGCGTG-CTGTCCCGGGT-3Ј, which correspond to nucleotide positions 27452-27473 and 27709-27687, respectively, of the human XRRC1 DNA sequence (accession number L34079) and allow amplification of a 258 bp fragment, corresponding to exon 9. The MPG cDNA probe was previously described. 14, 26 The GAPDH probe, a 0.9 kb EcoRI fragment of the human glyceraldehyde-3-phosphate dehydrogenase (GAPDH) gene, was a generous gift from Dr R Dalla Favera (Department of Pathology, Columbia University, New York, NY, USA). Bidimensional densitometry of the blots was performed using a scanning apparatus Imaging densitometer, GS-670 (BioRad, Richmond, CA, USA).
Results
Treatment with PADPRP inhibitors increases susceptibility to cytotoxicity induced by TZM in leukemia cells tolerant to O
-methylguanine
In order to study the kinetics of cell growth inhibition and apoptosis induction by TZM combined with PADPRP inhibitors in cells tolerant to O 6 -methylguanine, Jurkat cells, endowed with high OGAT levels 10 and deficient in MRS, 22 were exposed to graded concentrations of TZM alone, or combined with ABZ or NU1025. The results of the analysis of Jurkat cell growth (Figure 1 ) indicate that treatment with TZM alone partially inhibited the growth of these cells, with respect to untreated controls (Figure 1a) . In contrast, when TZM was associated either with ABZ or NU1025 a marked reduction of Jurkat cell growth was observed, at all the TZM concentrations tested (Figure 1b and c) . Actually, when the cells were exposed to 500 M TZM and each PADPRP inhibitors, the number of cells evaluated after 72 h of culture was the same as the total number of cells plated on day 0. Moreover, the growth inhibitory effect could be detected as early as 24 h after drug exposure. 
Analysis of apoptosis induced by TZM combined with ABZ
Cleavage of cellular DNA into high molecular weight (predominantly 50 kb) fragments has been recognized as an early event during apoptosis. 25 In order to test whether the growth inhibitory effect, observed 24 h after treatment was associated with apoptosis, untreated cells or cells treated with ABZ + TZM were analyzed by PFGE. The results, illustrated in Figure 2 show the appearance of DNA fragments in the range of 50 kb following treatment with ABZ + TZM. This was particularly evident at the highest TZM concentration, whereas it was barely visible in cells treated with 500 M TZM alone (Figure 2, upper panel) . Moreover, the proteolytic cleavage of PADPRP protein, 27 an early marker of apoptosis which parallels DNA fragmentation, was clearly detectable only in those cells exposed to the drug combination (Figure 2, lower panel) .
Flow cytometry analysis, after staining of the cells with PI, allows the detection of apoptotic cells with a reduced DNA content, which are represented by a broad hypodiploid peak. This feature of the apoptotic cells parallels the morphological changes (eg apoptotic bodies), which are regarded as a later event with respect to the cleavage of DNA into high molecular weight fragments. The results of flow cytometry analysis of Jurkat cells, 24 h after treatment with TZM in combination with ABZ or NU1025, indicated only a marginal increase in the percentage of cells characterized by a reduced DNA content, with respect to cells, untreated, treated with PADPRP inhibitors or with TZM only (data not shown). In contrast, 48 h after drug exposure, the association of ABZ or NU1025 with TZM induced a more pronounced increase of the percentage of cells with hypodiploid DNA content, with respect to treatment with TZM alone (Figure 3) . Previous studies performed in a different model system showed that PADPRP inhibitors suppress nuclear fragmentation and apoptotic body formation without affecting chromatin condensation or DNA fragmentation during apoptosis induced by Actinomycin D in a leukemia cell line. 28 The results of confocal microscopy analysis in our model system revealed that PADPRP inhibitors, when associated with TZM, induced the characteristic apoptotic morphological changes such as apoptotic bodies in Jurkat cells (Figure 4b ). When treated with TZM alone cells showed similar morphological changes (Figure 4c ). However, it should be noted that in the latter group apoptotic cells were only a limited number (Figure 3g) .
Analysis of the transcripts of genes involved in DNA repair
Jurkat cells are MRS-deficient and therefore unable to process O 6 -methylguanine, which is responsible for the cytotoxicity induced by methylating agents in MRS-proficient cells. It is reasonable to hypothesize that the cytotoxic effects induced by the combination of TZM and PADPRP inhibitors could be due to inhibition of BER-mediated repair of adducts located at DNA sites different from O 6 -guanine. It is reasonable to assume that reduction of repair enzyme levels would be followed by upregulation of the expression of the relevant genes. Therefore, the levels of the transcripts of genes involved in the BER process have been investigated in untreated and treated Jurkat cells. In particular, we have studied the expression of PADPRP, MPG and XRCCI at the RNA level, 24 h after drug treatment. The results of Northern blot analysis are illustrated in Figures 5 and 6 . The hybridization signals were quantified by densitometric scanning of the autoradiograms and normalized in relation to the expression of the GAPDH gene. The optical density ratio between treated and control groups is also represented in the histograms of each figure. The results of Northern blot analysis of XRCC1 indicate that only cells treated with the drug combination expressed higher levels of this transcript with respect to ABZ treated or untreated controls ( Figure 5 ). In this case, exposure to ABZ or to TZM alone did not affect the expression of XRCC1.
The results illustrated in Figure 6 indicate that: (1) ABZ treatment resulted in augmented expression of MPG and PADPRP transcripts with respect to untreated control (see legend to Figure 6) ; (2) TZM alone increased MPG and PADPRP transcripts with respect to those of the untreated control; (3) TZM combined with ABZ increased MPG and PADPRP transcripts with respect to those detected in cells treated with ABZ alone; and (4) the level of increase of MPG and PADPRP transcripts observed with the drug combination was similar to that induced by the treatment with TZM alone (see legend to Figure 6 ). 
Discussion
The PADPRP enzyme is thought to play a multifunctional role in numerous cellular processes, including cell proliferation, DNA repair and apoptosis.
Recently, it has been demonstrated that PADPRP is involved in the detection of DNA strand interruptions and recruitment of components of BER complex to the damaged site. 15, 18 The BER system is devoted to the repair of DNA damages which arise spontaneously or from the reaction with oxygen-free radicals and alkylating agents. 29 In the case of methylating compounds, the N 3 -methyladenine and N 7 -methylguanine are the DNA damaged bases which are recognized and processed by the BER system.
Recent studies indicated that inhibition of PADPRP by chemical analogues of NAD + , overexpression of dominantnegative mutants, anti-sense RNA, or gene disruption, rendered cells more sensitive to strand break inducing agents. 23, [30] [31] [32] [33] The results of the present study indicate that PADPRP inhibitors increased susceptibility to the methylating agent TZM in leukemic Jurkat cells, which are tolerant to O 6 -methylguanine. Jurkat cells are MRS-deficient, due to an allelic loss of both hMSH2 and hMSH6 genes and to mutations in the remaining alleles of both genes of the MRS. 22 The cytotoxic and apoptotic effects induced by the drug combination were evident as early as 24 h after treatment. This observation suggested that the DNA damage, derived from unrepaired Nmethypurines, might account for the inhibition of cell proliferation already in the first round of cell division. In contrast, in MRS-proficient and OGAT-deficient leukemic cells, strand breaks derived from the processing of O 6 -methylguanine adducts required two cell divisions before the emergence of TZM cytotoxicity. 7, 34 The association of PADPRP function with apoptosis has been inferred by the occurrence of a transient poly(ADPribosyl)ation of nuclear proteins at an early stage of apoptosis and by its subsequent proteolytic cleavage. 27, 35 It has been hypothesized that PADPRP inactivation by apoptotic caspases might avoid unnecessary DNA repair during chromatin degradation. 36 In fact, it has been demonstrated that PADPRP-negative cells are extremely sensitive to apoptosis induced by alkylating agents which activates the BER pathway. 36 Our data indicate that the drug combination of PADPRP inhibitors and TZM induced the triggering of the apoptotic process, accompanied by PADPRP cleavage and the typical morphological changes of apoptosis.
The role of MPG and XRCC1 in protection against DNA damage induced by alkylating agents has been recently demonstrated, 37 thus indicating that inhibition of the BER pathway might increase susceptibility of tumor cells to these agents. Actually, MPG-deficient cells are highly sensitive to MeOSO 2 (CH 2 ) 2 -lexitrospin, an alkylating agent that forms almost exclusively N 3 -methyladenine adducts. 13 It has been assumed that N 3 -methyladenine might kill mammalian cells by blocking DNA replication. 13 Conversely, other authors reported that overexpression of MPG was followed by enhanced chemosensitivity to methylating agents, suggesting that apurinic sites, formed as a result of MPG action, might induce sister chromatid exchanges and chromosomal aberrations.
34
In our model system, represented by a leukemic cell line unable to process O 6 -methylguanine, it is reasonable to hypothesize that the cytotoxic and apoptotic effects of the combination of TZM and PADPRP inhibitors might be the consequence of strand interruptions derived from the removal of N-methylpurines and of the resulting apurinic residues. In fact, inhibition of the PADPRP function would prevent further repair of the damaged DNA by the other components of the BER system. Thus, persistence of strand breaks might hamper cell division and trigger the apoptotic process.
Increased levels of XRCC1 transcript were observed only in Jurkat cells exposed to the combination of ABZ and TZM. Recently, it has been demonstrated that XRCC1, preferentially binds to oligo(ADP-ribosylated)-PADPRP and then limits its further auto-(ADP-ribosylation), thus indicating a functional link between these proteins. 18 In our experimental conditions, it is possible to hypothesize that unrepaired strand breaks, due to inhibition of PADPRP, might trigger the synthesis of XRCC1 transcript in Jurkat cells treated with ABZ + TZM. This could be interpreted as a cellular response to the treatment aimed at increasing the efficiency of the repair system. Differently, increased levels of MPG or PADPRP transcripts occurred in Jurkat cells treated either with ABZ + TZM or with TZM alone. In the case of MPG, this could be due to the fact that a great number of MPG molecules are engaged in removing the large amounts of damaged bases present in the DNA of cells exposed to ABZ + TZM or TZM alone. Regarding PADPRP transcript, it is possible to hypothesize that resynthesis of PADPRP in TZM-treated cells might be due to the consumption of the enzyme, used to co-ordinate the repair of the DNA lesions. In contrast, the increase in the level of PADPRP transcript in cells exposed to the drug combination might be the consequence of the replacement of the enzyme, which might be inactivated and degraded following interaction with ABZ. Moreover, since it has been demonstrated that PADPRP protein was slightly augmented in the G2/M phase of the cell cycle, 38 it cannot be excluded that the increase of PADPRP transcript observed in cells exposed to the drug combination might also reflect cell progression from G1 to G2/M phase of cell cycle.
Deficiencies in the MRS function have been reported in human hematological malignancies. 39, 40 Mutations in the genes of the MRS have been recently detected in a number of human leukemia, colon and glioma cell lines, which show a methylator resistant phenotype and are not susceptible to cytotoxicity induced by TZM or by other methylating agents.
7,22,41,42 Therefore, in these cases, the inhibition of PADPRP and consequently of the repair of DNA adducts different from O 6 -methylguanine might represent a valuable strategy for overcoming drug resistance.
In conclusion, our results suggest that for all the malignancies in which TZM has shown promising or potential activity, the combination with a PADPRP inhibitor might be of considerable benefit in those cases, which do not respond to the drug, due to a defect in the MRS function.
